COVID-19 and Cancer Consortium Registry
In this study we will collect granular information on cancer patients infected with COVID-19, as rapidly as possible. The mechanism for collection of this information is a de-identified centralized registry housed at Vanderbilt University Medical Center, with data donations from internal and external health care professionals.
Checked against the public recordLast updated Jan 9, 2024 · Source: ClinicalTrials.gov
What this study is about
- Purpose
- Not specified
- Study type
- Observational
- Phase
- Not applicable
- Sponsor
- Vanderbilt-Ingram Cancer Center
- Interventions being studied
- Other: Web-based REDCap survey
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
Inclusion criteria: • Healthcare providers or their proxies who would like to report a patient with ALL of the following criteria: * Suspected (presumptive positive based on clinical presentation) or lab-confirmed COVID-19. * Current or past medical history of invasive malignancy (any type) Exclusion criteria: * Participants at international sites not explicitly listed below * Non-healthcare providers (or their proxies)
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- Vanderbilt University Medical CenterNashville, Tennessee
Source and freshness
Processed from ClinicalTrials.gov. Last public update: Jan 9, 2024. Always confirm current availability with the study team.